Abstract: The present invention relates to methods of treatment or prevention of irritable bowel syndrome (IBS), abdominal pain, disordered defecation, and FODMAP intolerance, by administering a preparation containing probiotic strain of Lactobacillus plantarum (Lactiplantibacillus plantarum) DSM 33363, or the preparation in combination with Lactobacillus plantarum (Lactiplantibacillus plantarum) DSM 33364, Lactobacillus paracasei (Lacticaseibacillus paracasei) DSM 33373, Lactobacillus resuteri (Limosilactobacillus reuteri) DSM 33374, Bacillus megaterium (Priestia megaterium) DSM 33300, Bacillus pumilus DSM 33297, and Bacillus pumilus DSM 33355, as viable cells or cytoplasmic extract thereof. A foodstuff composition containing the preparation disclosed herein is also described.

Abstract: The use of a probiotic composition includes the probiotic strains Lactobacillus plantarum (Lactiplantibacillus plantarum) DSM 33363, Lactobacillus plantarum (Lactiplantibacillus plantarum) DSM 33364, Lactobacillus paracasei (Lacticaseibacillus paracasei) DSM 33373, Lactobacillus reuteri (Limosilactobacillus reuteri) DSM 33374, Bacillus megaterium (Priestia megaterium) DSM 33300, Bacillus pumilus DSM 33297, Bacillus pumilus DSM 33355 (the “Pro-nutrient” consortium), for treating and preventing malnutrition of humans and animals by increasing the nutritional value of cereal-based foodstuffs, derived from wheat in particular, through increasing the bioavailability of essential micronutrients and amino acids contained in these foodstuffs.

Abstract: A synbiotic preparation contains at least one probiotic strain and at least one amino acid or derivative displaying an effect in glucose metabolism management, such as diabetes prevention or prediabetes treatment. The preparation modulates satiety hormones, such as CCK, GLP-1, and PYY. Methods are developed to treat obesity, adiposity, type 2 diabetes, and metabolic syndrome with the preparation. A preparation also decreases fasting glucose levels in a subject.

Abstract: The invention discloses preparations for use in enhancing formation of short-chain fatty acids (SCFAs) in a subject for treating or preventing a disease or disorder comprising at least one omega-3 fatty acid salt having an organic counter ion selected from lysine, arginine, ornithine, choline and mixtures of the same, wherein the omega-3 fatty acid is selected from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and a colon-specific delivery system.

Abstract: A synbiotic preparation may include at least one probiotic strain and at least one amino acid or derivative thereof selected from glutamine, glutamic acid or salts thereof, conjugated glutamine, or oligopeptides of 2-10 amino acid units in length, wherein the amino acid units may be natural amino acids, and at least one amino acid unit being a glutamine or glutamic acid unit.

Abstract: Preparations may include at least one extract of gum resins from Boswellia species and at least one omega-3 fatty acid salt selected from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Surprisingly, such combinations of extracts of gum resins from Boswellia species and polyunsaturated fatty acid salt can cause a marked and unexpected increase in the biosynthesis of specialized pro-resolving mediators (SPM) in a synergistic manner, proposing benefit for resolution of inflammatory conditions.

Abstract: A preparation containing a mixture of at least one phospholipid, and at least one fatty acid salt of a cation with an anion derived from a fatty acid. A method for preparing such preparation and the use of such preparation to provide polyunsaturated fatty acids to cells, tissues, organs or organisms, for example in the field of cell and tissue culture, organ preservation, human or animal nutrition, or cosmetics.

Abstract: Preparations can be used for treating or preventing dysbiosis in humans and animals. The preparation has the probiotic strains Lactobacillus plantarum DSM 33363, Lactobacillus plantarum DSM 33364, Lactobacillus paracasei DSM 33373, Lactobacillus reuteri DSM 33374, Bacillus megaterium DSM 33300, Bacillus pumilus DSM 33297, and Bacillus pumilus DSM 33355.

Abstract: The current invention concerns preparations comprising probiotic strains belonging to the genus Lactobacillus in combination with the amino acid L-tryptophan.

Abstract: The current invention concerns preparations comprising at least one probiotic strain belonging to the species Lactobacillus helveticus, Lactobacillus rhamnosus (Lacticaseibacillus rhamnosus), Lactobacillus mucosae (Limosilactobacillus mucosae), and Lactobacillus johnsonii and anthocyanins.

Abstract: A preparation comprising probiotic strains belonging to the genera Bacillus sp., Lactobacillus sp., optionally Pediococcus sp. as viable cells or cytoplasmic extract thereof, and proteases, wherein the strains can degrade peptide sequences of gliadins. The preparation can be used to produce gluten-free foods from gluten-containing cereals or to treat gluten-related disorders.

Abstract: This invention concerns a process to identify consortia of probiotic strains belonging to e.g. the genera Lactobacillus, Bacillus, Pediococcus, and Weissella that can be used in preparations for food supplement, food production, and pharmaceutical applications with the intention to execute a safe and rapid degradation of gluten to non-toxic, non-immunogenic digests.

Abstract: The invention discloses preparations for use in enhancing formation of short-chain fatty acids (SCFAs) in a subject for treating or preventing a disease or disorder comprising at least one omega-3 fatty acid salt having an organic counter ion selected from lysine, arginine, ornithine, choline and mixtures of the same, wherein the omega-3 fatty acid is selected from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and a colon-specific delivery system.

Abstract: Preparations may include at least one extract of gum resins from Boswellia species and at least one omega-3 fatty acid salt selected from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Surprisingly, such combinations of extracts of gum resins from Boswellia species and polyunsaturated fatty acid salt can cause a marked and unexpected increase in the biosynthesis of specialized pro-resolving mediators (SPM) in a synergistic manner, proposing benefit for resolution of inflammatory conditions.

Abstract: The invention discloses preparations comprising L-rhamnose, and the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the form of either free fatty acids, fatty acid salts having an organic counter ion selected from lysine, arginine, ornithine, choline and mixtures of the same, or mixtures of free fatty acids and omega-3 fatty acid salts having an organic counter ion selected from lysine, arginine, ornithine, choline and use of a preparation as a feed or food supplement or in pharmaceutical compositions.

Abstract: A synbiotic preparation may include at least one probiotic strain and at least one amino acid or derivative thereof selected from glutamine, glutamic acid or salts thereof, conjugated glutamine, or oligopeptides of 2-10 amino acid units in length, wherein the amino acid units may be natural amino acids, and at least one amino acid unit being a glutamine or glutamic acid unit.

Abstract: A preparation containing a mixture of at least one phospholipid, and at least one fatty acid salt of a cation with an anion derived from a fatty acid. A method for preparing such preparation and the use of such preparation to provide polyunsaturated fatty acids to cells, tissues, organs or organisms, for example in the field of cell and tissue culture, organ preservation, human or animal nutrition, or cosmetics.

Abstract: The invention relates to preparation comprising at least one omega-3 or omega-6 fatty acid component selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), alpha linolenic acid, stearidonic acid, eicosatetraenoic acid, docosapentaenoic acid, linoleic acid, ?-linolenic acid, or arachidonic acid (ARA) and/or derivatives thereof for use to increase the formation of one or more specialized pro-resolving lipid mediators (SPM) by gastrointestinal microorganisms in the gastrointestinal tract of humans or animals wherein the polyunsaturated fatty acid component comprises an omega-3 or omega-6 fatty acid salt.

Abstract: The invention relates to preparation comprising at least one probiotic strain belonging to the genus Bacillus megaterium, and a polyunsaturated fatty acid component comprising at least one omega-3 or omega-6 fatty acid selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid (ARA), alpha linolenic acid, stearidonic acid, eicosatetraenoic acid, docosapentaenoic acid, linoleic acid, ?-linolenic acid, wherein the polyunsaturated fatty acid component comprises an omega-3 or omega-6 fatty acid salt. The invention further relates to use of the inventive preparation as a feed or food supplement, pharmaceutical product, feed-or foodstuff compositions and for topical applications.